Biogen's stance at the upcoming AD/PD 2024 International Conference on Alzheimer's disease and Parkinson's disease will demonstrate its future plans for treating Alzheimer's, following the discontinuation of Aduhelm (aducanumab), its anti-amyloid beta (AÎ) monoclonal antibody (mAb).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,